The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.
申请公布号
WO2015112601(A1)
申请公布日期
2015.07.30
申请号
WO2015US12248
申请日期
2015.01.21
申请人
IVAX INTERNATIONAL GMBH;TEVA PHARMACEUTICALS USA, INC.;LICHT, DANIELLA;LOVINGER, IOANA;GUILATT, LAURA YEHUDIT;BASSAN, MERAV
发明人
LICHT, DANIELLA;LOVINGER, IOANA;GUILATT, LAURA YEHUDIT;BASSAN, MERAV